203 related articles for article (PubMed ID: 30282812)
1. mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Ther; 2018 Dec; 17(12):2676-2688. PubMed ID: 30282812
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
3. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine.
Goss KL; Koppenhafer SL; Harmoney KM; Terry WW; Gordon DJ
Oncotarget; 2017 Oct; 8(50):87016-87032. PubMed ID: 29152060
[TBL] [Abstract][Full Text] [Related]
5. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
6. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
[TBL] [Abstract][Full Text] [Related]
7. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
8. Activator Protein-1 (AP-1) Signaling Inhibits the Growth of Ewing Sarcoma Cells in Response to DNA Replication Stress.
Croushore EE; Koppenhafer SL; Goss KL; Geary EL; Gordon DJ
Cancer Res Commun; 2023 Aug; 3(8):1580-1593. PubMed ID: 37599787
[TBL] [Abstract][Full Text] [Related]
9. Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Morimoto Y; Takada K; Takeuchi O; Takagi A; Watanabe K; Hirohara M; Hamamoto T; Masuda Y
Oncol Rep; 2020 Feb; 43(2):689-699. PubMed ID: 31789403
[TBL] [Abstract][Full Text] [Related]
10. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Walton MI; Eve PD; Hayes A; Valenti M; De Haven Brandon A; Box G; Boxall KJ; Aherne GW; Eccles SA; Raynaud FI; Williams DH; Reader JC; Collins I; Garrett MD
Mol Cancer Ther; 2010 Jan; 9(1):89-100. PubMed ID: 20053762
[TBL] [Abstract][Full Text] [Related]
11. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
13. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
14. High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
Wang S; Hwang EE; Guha R; O'Neill AF; Melong N; Veinotte CJ; Conway Saur A; Wuerthele K; Shen M; McKnight C; Alexe G; Lemieux ME; Wang A; Hughes E; Xu X; Boxer MB; Hall MD; Kung A; Berman JN; Davis MI; Stegmaier K; Crompton BD
Clin Cancer Res; 2019 Jul; 25(14):4552-4566. PubMed ID: 30979745
[TBL] [Abstract][Full Text] [Related]
15. CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress.
Li F; Kozono D; Deraska P; Branigan T; Dunn C; Zheng XF; Parmar K; Nguyen H; DeCaprio J; Shapiro GI; Chowdhury D; D'Andrea AD
Mol Cell; 2020 Nov; 80(3):410-422.e6. PubMed ID: 33108758
[TBL] [Abstract][Full Text] [Related]
16. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
[TBL] [Abstract][Full Text] [Related]
17. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
18. CDK12 phosphorylates 4E-BP1 to enable mTORC1-dependent translation and mitotic genome stability.
Choi SH; Martinez TF; Kim S; Donaldson C; Shokhirev MN; Saghatelian A; Jones KA
Genes Dev; 2019 Apr; 33(7-8):418-435. PubMed ID: 30819820
[TBL] [Abstract][Full Text] [Related]
19. Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells.
Zhang C; Yang L; Geng YD; An FL; Xia YZ; Guo C; Luo JG; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 May; 7(19):27819-37. PubMed ID: 27056897
[TBL] [Abstract][Full Text] [Related]
20. The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Parsels LA; Parsels JD; Tanska DM; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2018; 17(9):1076-1086. PubMed ID: 29895190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
